Preimplantation Genetic Testing Market Size & Share, By Product, Procedure, Technology, Application, End-use, Regional Forecast, Industry Players, Growth Statistics Report 2024-2032

Market Outlook:

Preimplantation Genetic Testing Market was over USD 808.71 Million in 2023 and is poised to surpass USD 1.49 Billion by end of the year 2032, growing at over 7.1% CAGR between 2024 and 2032.

• Base Year Value (2023): USD 808.71 Million
• CAGR (2024-2032): 7.1%
• Forecast Year Value (2032): USD 1.49 Billion
• Historical Data Period: 2019-2023
• Largest Region: Europe
• Forecast Period: 2024-2032

Market Dynamics:

Growth Drivers & Opportunity:

1. Increasing awareness and acceptance of Preimplantation Genetic Testing (PGT) among individuals seeking assisted reproductive technologies.

2. Technological advancements leading to the development of new and more efficient PGT techniques.

3. Rising prevalence of genetic disorders and chromosomal abnormalities driving the demand for PGT services.

Report Scope

Report Coverage	Details
Segments Covered	Procedure, Product, Technology, Application, End-Use
Regions Covered	• North America (United States, Canada, Mexico) • Europe (Germany, United Kingdom, France, Italy, Spain, Rest of Europe) • Asia Pacific (China, Japan, South Korea, Singapore, India, Australia, Rest of APAC) • Latin America (Argentina, Brazil, Rest of South America) • Middle East & Africa (GCC, South Africa, Rest of MEA)
Company Profiled	Quest Diagnostics Incorporated, Natera,, COOPER SURGICAL, INC., Genea Pty Limited., Invitae, Laboratory of America Holdings, Thermo Fisher Scientific, Bioarray S.L., Illumina,, Igenomix, RGI, F. Hoffmann-La Roche

Industry Restraints:

1. High cost associated with PGT procedures limiting access for a significant portion of the population.

2. Ethical and regulatory concerns surrounding the use of PGT technology, leading to potential restrictions on its widespread adoption.

Regional Forecast:

North America: The Preimplantation Genetic Testing market size in North America, particularly in the U.S. and Canada, is expected to witness significant growth due to the presence of advanced healthcare infrastructure, increasing awareness about genetic testing, and high adoption rates of advanced technologies in the region.

2. Asia Pacific: The Preimplantation Genetic Testing market in Asia Pacific, including countries like China, Japan, and South Korea, is expected to experience rapid growth due to the increasing prevalence of genetic disorders, rising healthcare expenditure, and growing demand for advanced genetic testing technologies in the region.

3. Europe: The Preimplantation Genetic Testing market in Europe, specifically in the United Kingdom, Germany, and France, is anticipated to witness steady growth owing to the presence of well-established healthcare systems, supportive government initiatives, and increasing focus on precision medicine and personalized healthcare in the region.

Segmentation Analysis:

In terms of segmentation, the global Preimplantation Genetic Testing market is analyzed on the basis of Procedure, Product, Technology, Application, End-Use.

1. By Product:

The Preimplantation Genetic Testing (PGT) market can be segmented by product into instruments, reagents and consumables, and software and services. Instruments include machines and equipment used for testing genetic material, while reagents and consumables consist of chemicals and supplies needed for the testing process. Software and services encompass the technological platforms and support services required for analyzing and interpreting genetic data.

2. By Procedure:

PGT procedures can be categorized into preimplantation genetic screening (PGS) and preimplantation genetic diagnosis (PGD). PGS involves screening embryos for chromosomal abnormalities, while PGD is used to detect specific genetic disorders in embryos before implantation. Both procedures play a crucial role in identifying and selecting healthy embryos for assisted reproductive technologies.

3. By Technology:

The technology segment of the PGT market includes polymerase chain reaction (PCR), next-generation sequencing (NGS), fluorescent in situ hybridization (FISH), and comparative genomic hybridization (CGH). These technologies are utilized for analyzing genetic material in embryos and identifying any abnormalities or mutations that may impact the health of the offspring.

4. By Application:

PGT is primarily used for applications such as identifying genetic disorders, screening for chromosomal abnormalities, and determining the sex of embryos. This technology is crucial for ensuring the health and well-being of offspring conceived through in vitro fertilization (IVF) by selecting genetically normal embryos for implantation.

5. By End-use:

The end-use segment of the PGT market includes fertility clinics, research laboratories, and hospitals. Fertility clinics are the primary users of PGT technology, as they perform genetic testing on embryos before implantation during IVF procedures. Research laboratories are involved in developing and validating new PGT technologies, while hospitals may offer PGT services as part of their reproductive medicine departments.

Competitive Landscape:

The competitive landscape in the Preimplantation Genetic Testing Market is characterized by a mix of established players and emerging companies, all vying for a share of this rapidly growing sector. Key factors driving competition include technological advancements in genetic testing procedures, increasing awareness about genetic disorders, and rising demand for IVF services across various regions. Companies are focusing on innovation, enhancing accuracy, and reducing costs of genetic testing to gain a competitive edge. Additionally, strategic partnerships, mergers, and collaborations are being pursued to expand service offerings and geographical reach. The market is witnessing significant investment in research and development to advance testing methodologies, and improve patient outcomes, further intensifying competition.

Top Market Players

- Illumina, Inc.

- Thermo Fisher Scientific Inc.

- Agilent Technologies, Inc.

- Fulgent Genetics, Inc.

- Natera, Inc.

- CooperSurgical, Inc.

- Preimplantation Genetic Diagnosis (PGD) Laboratory

- Reproductive Genetics Institute

- Genomic Prediction, Inc.

- Myriad Genetics, Inc.